Literature DB >> 18453798

Cardiovascular disease in blacks: can we stop the clock?

Keith C Ferdinand1.   

Abstract

Blacks have the highest rates of hypertension and cardiovascular disease, with earlier onset, greater severity, and more target organ damage including coronary disease, heart failure, stroke, and end-stage renal disease. A major reason is the greater prevalence of other cardiovascular disease risk factors, particularly obesity, inactivity, and diabetes mellitus, along with socioeconomic differences, adherence, and achievement of goals. This review focuses on the burden of cardiovascular disease in blacks. Therapeutic lifestyle changes and pharmacologic interventions to decrease clinical events in this high-risk group are described. Intensive blood pressure control is a primary means of "stopping the clock" in the progression of cardiovascular disease and renal disease. Thiazide diuretics remain primary first-step agents, especially for uncomplicated hypertension; calcium channel blockers are also efficacious. However, renin-angiotensin system modulators may also be beneficial, especially with a diuretic, considering the high prevalence in this group of patients of compelling indications for use of such agents.

Entities:  

Mesh:

Year:  2008        PMID: 18453798      PMCID: PMC8109939          DOI: 10.1111/j.1751-7176.2008.07918.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  38 in total

1.  Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.

Authors:  Janice G Douglas; George L Bakris; Murray Epstein; Keith C Ferdinand; Carlos Ferrario; John M Flack; Kenneth A Jamerson; Wendell E Jones; Julian Haywood; Randall Maxey; Elizabeth O Ofili; Elijah Saunders; Ernesto L Schiffrin; Domenic A Sica; James R Sowers; Donald G Vidt
Journal:  Arch Intern Med       Date:  2003-03-10

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

Authors:  Keith Norris; Jacque Bourgoigne; Jennifer Gassman; Lee Hebert; John Middleton; Robert A Phillips; Otelio Randall; Stephen Rostand; Susan Sherer; Robert D Toto; Jackson T Wright; Xuelei Wang; Tom Greene; Lawrence J Appel; Julia Lewis
Journal:  Am J Kidney Dis       Date:  2006-11       Impact factor: 8.860

4.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

Authors:  William J Elliott; Peter M Meyer
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

5.  Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States.

Authors:  Nathan D Wong; Victor Lopez; Simon Tang; G Rhys Williams
Journal:  Am J Cardiol       Date:  2006-05-11       Impact factor: 2.778

6.  Responses to captopril and hydrochlorothiazide in black patients with hypertension.

Authors:  M Moser; J Lunn
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

7.  Effect of ramipril on the incidence of diabetes.

Authors:  Jackie Bosch; Salim Yusuf; Hertzel C Gerstein; Janice Pogue; Patrick Sheridan; Gilles Dagenais; Rafael Diaz; Alvaro Avezum; Fernando Lanas; Jeffrey Probstfield; George Fodor; Rury R Holman
Journal:  N Engl J Med       Date:  2006-09-15       Impact factor: 91.245

8.  Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial.

Authors:  L P Svetkey; D Simons-Morton; W M Vollmer; L J Appel; P R Conlin; D H Ryan; J Ard; B M Kennedy
Journal:  Arch Intern Med       Date:  1999-02-08

9.  The burden of adult hypertension in the United States 1999 to 2000: a rising tide.

Authors:  Larry E Fields; Vicki L Burt; Jeffery A Cutler; Jeffrey Hughes; Edward J Roccella; Paul Sorlie
Journal:  Hypertension       Date:  2004-08-23       Impact factor: 10.190

Review 10.  Hypertension-related morbidity and mortality in African Americans--why we need to do better.

Authors:  Keith C Ferdinand; Elijah Saunders
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

View more
  8 in total

1.  Differences in ocular blood flow in glaucoma between patients of African and European descent.

Authors:  Brent Siesky; Alon Harris; Lyne Racette; Rania Abassi; Kaarthik Chandrasekhar; Leslie A Tobe; Jennifer Behzadi; George Eckert; Annahita Amireskandari; Michael Muchnik
Journal:  J Glaucoma       Date:  2015-02       Impact factor: 2.503

2.  Mathematical modeling approaches in the study of glaucoma disparities among people of African and European descents.

Authors:  Giovanna Guidoboni; Alon Harris; Julia C Arciero; Brent A Siesky; Annahita Amireskandari; Austin L Gerber; Andrew H Huck; Nathaniel J Kim; Simone Cassani; Lucia Carichino
Journal:  J Coupled Syst Multiscale Dyn       Date:  2013-04-01

3.  Prescribing patterns in the treatment of hypertension among underserved African American elderly.

Authors:  Hamed Yazdanshenas; Mohsen Bazargan; Gail Orum; Leila Loni; Navid Mahabadi; Baqar Husaini
Journal:  Ethn Dis       Date:  2014       Impact factor: 1.847

4.  Ocular blood flow as it relates to race and disease on glaucoma.

Authors:  Brent Siesky; Alon Harris; Alice C Verticchio Vercellin; Giovanna Guidoboni; James C Tsai
Journal:  Adv Ophthalmol Optom       Date:  2021-07-12

Review 5.  Vascular considerations in glaucoma patients of African and European descent.

Authors:  Andrew Huck; Alon Harris; Brent Siesky; Nathaniel Kim; Michael Muchnik; Priyanka Kanakamedala; Annahita Amireskandari; Leslie Abrams-Tobe
Journal:  Acta Ophthalmol       Date:  2014-01-25       Impact factor: 3.761

Review 6.  The role of ethnicity, age and gender in venous thromboembolism.

Authors:  Martina Montagnana; Emmanuel J Favaloro; Massimo Franchini; Gian Cesare Guidi; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

7.  Ocular blood flow as a clinical observation: Value, limitations and data analysis.

Authors:  Alon Harris; Giovanna Guidoboni; Brent Siesky; Sunu Mathew; Alice C Verticchio Vercellin; Lucas Rowe; Julia Arciero
Journal:  Prog Retin Eye Res       Date:  2020-01-24       Impact factor: 21.198

8.  Sex-, Race- and Ethnicity-Based Differences in Thromboembolic Events Among Adults Hospitalized With COVID-19.

Authors:  Sadia Ilyas; Stanislav Henkin; Pablo Martinez-Camblor; Bjoern D Suckow; Jocelyn M Beach; David H Stone; Philip P Goodney; Joseph E Ebinger; Mark A Creager; Jesse A Columbo
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.